---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-242437"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2022-09-12T23:59:59+00:00"
generated_at: "2026-06-23T11:14:38.380419+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TScan secures up to $60M convertible debt facility with K2 HealthVentures; initial $30M tranche funds

## Summary
- Loan and Security Agreement with K2 HealthVentures for up to $60M in convertible term loans.
- First tranche of $30M fully funded at closing; second $10M and third $20M tranches subject to milestones and lender discretion.
- Loans mature September 1, 2026; interest-only payments for 24 months (extendable to 36 on milestones), then amortize.
- Interest rate is greater of 8.75% or Prime + 4.75%, capped at 9.90%; loan convertible at $4.785/share for first tranche.
- Cash runway extended into Q2 2024; funds to support IND filings and solid tumor multiplexing trials.

## SEC filing metadata
- accession: 0001193125-22-242437
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2022-09-12T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312522242437/0001193125-22-242437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312522242437/d323376d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-242437
- JSON: https://secwatch.observer/filing/0001193125-22-242437.json
- Plain text: https://secwatch.observer/filing/0001193125-22-242437.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.